MA242 is a Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy. MA242 decreased cell proliferation and induced apoptosis in pancreatic cancer cell lines regardless of p53 status. MA242 alone or in combination with gemcitabine inhibited pancreatic tumor growth and metastasis without any host toxicity. Our data indicate that targeting both MDM2 and NFAT1 represents a novel and effective strategy to treat pancreatic cancer. References: Wang W, Qin JJ, Voruganti S, Nijampatnam B, Velu SE, Ruan KH, Hu M, Zhou J, Zhang R. Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy. Cancer Res. 2018 Oct 1;78(19):5656-5667. doi: 10.1158/0008-5472.CAN-17-3939. Epub 2018 Sep 14. PubMed PMID: 30217928.

纯度：≥98%

CAS：1049704-18-8